Piribedil - A non-ergot dopamine agonist with a unique receptor profile;Piribedil - Ein non-ergot Dopaminagonist mit besonderem Rezeptorprofil: Ergebnisse von zwei studien bei patienten mit idiopathischem parkinsonsyndrom im klinischen alltag

Nervenheilkunde

Volumn 29, Issue 9, 2010, Pages 571-577

  Jost, Wolfgang ^a   Retzow, A ^b   Kuhn, K ^b  

^a DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^b ALK SCHERAX Arzneimittel GmbH   (Germany)

Author keywords

Non ergot dopamine agonist; Parkinson's disease; Piribedil; Vigilance

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; PIRIBEDIL;

ALERTNESS; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; PARKINSON DISEASE; SYMPTOM; THERAPY; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 77957983697     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1628814     Document Type: Article

References (8)

1. Castro-Caldas A, Delwaide P, Jost W et al. The Parkinson-Control Study: A 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Mov Disord 2006; 21: 500-509.
2. Lebrun-Frenay C, Borg M. Choosing the right dopamine agonist for patients with Parkinson's disease. Curr Med Res Opin 2002; 18: 209-214.
3. Lees A, Castro Caldas A, Dubois B et al. Two-year results of the REGAIN study, a placebo-controlled trial with the non-ergot dopamine agonist piribedil as early treatment in Parkinson's disease (PD). Eur J Neurol 2005; 12 (Suppl 2): 15.
4. Millan MJ, Peglion JL, Vian J et al. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective (+)-S 14297. Activation of postsynaptic receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther 1995; 275: 885-898. (Pubitemid 26027050)
5. Millan MJ Cussac D, Milligan G et al. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human a2-adrenoreceptors: cellular and functional characterization. J Pharmacol Exp Ther 2001; 297: 876-887.
6. Nagaraja D, Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 2001; 158: 1517-1519.
7. Rascol R, Dubois B, Castro Caldas A et al. Early Piribedil Monotherapy of Parkinson's Disease: A Planned Seven-Month Report of the REGAIN Study. Mov Dis 2006; 21: 2110-2115.
8. Schück S, Bentue-Ferrer D, Kleinermans D et al. Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers. Fundam Clin Pharmacol 2002; 16: 57-65.